Comparative Pharmacology
Head-to-head clinical analysis: DANOCRINE versus ORETON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DANOCRINE versus ORETON.
DANOCRINE vs ORETON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Danazol is a synthetic androgen derived from ethisterone. It suppresses the pituitary-ovarian axis by inhibiting gonadotropin (LH and FSH) release, leading to anovulation and amenorrhea. It also binds to androgen, progesterone, and glucocorticoid receptors, exerting weak androgenic, antiestrogenic, and antigonadotropic effects. Additionally, it may directly inhibit ovarian steroidogenesis and increase clearance of endogenous sex hormones.
Androgen receptor agonist; binds to androgen receptors, stimulating protein synthesis, growth of male reproductive tissues, and development of secondary sexual characteristics.
100-200 mg orally twice daily for endometriosis; 200-400 mg twice daily for fibrocystic breast disease; 200 mg twice daily for hereditary angioedema. Maximum dose: 800 mg/day.
Testosterone enanthate 50-400 mg IM every 2-4 weeks.
None Documented
None Documented
Terminal elimination half-life: 10–30 hours (mean 15 hours); clinically, steady-state reached after 2–4 days.
8 hours for testosterone; clinical context: requires daily or weekly dosing for replacement therapy
Renal (metabolites, ~50%), biliary/fecal (~30%), unchanged drug minimal.
Renal (90% as metabolites, 5% unchanged), biliary/fecal (10%)
Category C
Category C
Androgen/Antigonadotropin
Androgen